Reference pricing models are emerging as increasingly popular approaches for lowering drug costs.
David Henka
Advertisement
Articles by David Henka
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Why biosimilars keep losing ground to brand-name rivals: A Q&A with Christine Johnston, MBA
2
Melanoma care is shifting to risk-based screening and treatment before surgery | Fall Clinical Derm 2026
3
Jenny Hsiao, M.D., says HS biologics need time to work | Fall Clinical Derm 2026
4
Choosing a first biologic for HS, as recommended by Jennifer Hsiao, M.D. | Fall Clinical Derm 2026
5